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Personal View (Lancet Psychiatry) 
 
NICE Guidance on psychological treatments for bipolar disorder: searching for the 
evidence. 
 
The revised National Institute for Health and Care Excellence (NICE) Bipolar Guideline 185 
(CG185)1, which appeared in September 2014, makes a number of recommendations about 
psychological treatments. These cover the acute treatment of people with bipolar depression 
and the longer-term management of adults in secondary care (there are no recommendations 
about the psychological management of mania). Specifically, NICE recommend that people 
with bipolar depression in primary care and adults with bipolar depression in secondary care 
should be offered: 
 
- a psychological intervention that has been developed specifically for bipolar disorder 
and has a published evidence-based manual describing how it should be delivered, or 
a high-intensity psychological intervention (cognitive behavioural therapy, 
interpersonal therapy or behavioural couples therapy) in line with recommendations in 
the NICE clinical guideline on depression (recommendations 8.3.1.1 and 8.3.1.3). 
 
In the longer term, adults in secondary care should be offered: 
 
- a family intervention to people with bipolar disorder who are living, or in close 
contact, with their family in line with the NICE clinical guideline on psychosis and 
schizophrenia in adults (recommendation 8.3.1.5).  
 
and: 
 
- a structured psychological intervention (individual, group or family), which has been 
designed for bipolar disorder and has a published evidence based manual describing 
how it should be delivered, to prevent relapse or for people who have some persisting 
symptoms between episodes of mania or bipolar depression (recommendation 
8.3.1.6). 
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NICE clearly regards psychological interventions as important in bipolar disorder. The NICE 
Pathways, an online tool that acts as a quick and easy reference for NICE guidance 
(http://pathways.nice.org.uk), positions them as first line treatment for adults who are not in 
secondary care, and places them on an equal footing with pharmacological treatments in the 
longer-term management of the disorder. In these circumstances, the evidence on which the 
recommendations are based, and the decisions relating to how this is interpreted, need to be 
of the highest quality. 
 
 
The evidence base 
As always with NICE, the above recommendations are based on meta-analysis, in this case a 
series of meta-analyses that were commissioned from the National Collaborating Centre for 
Mental Health (NCCMH: available at http://www.nccmh.org.uk/downloads/). Perusing this 
documentation, the first thing that strikes the reader is the large number of meta-analyses that 
were conducted – there are around 170 meta-analyses of individual psychological 
interventions (plus a number of composite ones; see below). These examined therapies 
ranging from cognitive behavioural therapy (CBT) and mindfulness-based CBT, to 
psychoeducation and therapy for medication adherence, to niche interventions such as 
dialectical behaviour therapy, social cognition and interaction training and collaborative care. 
Outcomes considered included depressive and manic symptoms both at post-treatment and at 
follow-up, number of relapses, including all relapses and manic and depressive relapses, and 
also a range of social measures. Where possible, each therapy was separately considered 
when delivered individually and in a group format, and against treatment as usual (TAU) and 
other active treatments. As a result, each meta-analysis contained only a small numbers of 
trials – the largest was 6 – and over half included only one trial. 
 
When many analyses are performed, some of the findings will inevitably be positive at a 
significance level of 0.05 – the criterion that seems to have been adopted by NICE – purely 
by chance. Bonferroni correction, the classical method for dealing with this statistical 
problem, is notoriously strict, but other more appropriate methods exist, for example the false 
discovery rate (FDR) for non-independent variables2. However, no correction for multiple 
comparisons of any type was carried out by NCCMH.  
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The meta-analyses of acute treatment for bipolar depression 
The intervention with the most studies was CBT. As shown in Table 1, a meta-analysis of 6 
trials of individual CBT versus TAU gave a significant result in the small range (standardized 
mean difference [SMD] -0.31) at post-treatment. The benefit, however, was not maintained in 
4 trials that included follow-up data. Table 1 also shows that two meta-analyses of group 
CBT found no benefit at post-treatment or at follow-up. There were significant findings in 
two single-trial meta-analyses which compared CBT to an active control (supportive 
therapy), but in both cases these favoured the control intervention. 
 
Table 1. Meta-analyses of symptom reduction in bipolar depression with CBT 
  
 Assessment  
point 
Number  
of trials 
Effect Size (SMD) 
Individual CBT vs TAU  End 6 -.31 [-.53 to -.08] 
Individual CBT vs TAU  Follow up 4 -.19 [-.46 to +.08] 
Group CBT vs TAU  End 2 -.55 [-1.12 to +.02] 
Group CBT vs TAU  Follow-up 1 +.06 [-.48 to +.60] 
Individual CBT vs active control End 1 +.41 [+.12 to +.70] 
Individual CBT vs active control Follow-up 1 +.49 [+.04 to +94] 
SMD – standardized mean difference  
Negative effect sizes indicate that CBT is superior to control; positive effect sizes that CBT is 
worse than control 
 
The other intervention for which a substantial amount of information was available was 
psychoeducation. Two meta-analyses, each containing two trials, found no evidence of 
significant symptom reduction for online psychoeducation compared to TAU, either at post-
treatment (SMD -0.18 [-0.63 to +0.26]) or follow-up (SMD -0.36 [-1.09 to +0.37]). Group 
psychoeducation likewise had negative results versus TAU at post-treatment (SMD +0.14 [-
0.17 to +0.46], 2 trials) and follow-up (SMD +0.40 [-0.07 to +0.87], 1 trial). Family 
psychoeducation was found to be beneficial compared to TAU and to active control at post-
treatment  (SMD -0.73 [-1.35 to -0.10] and -0.40 [-0.80 to -0.00], respectively) but not at 
follow-up (SMD -0.15 [-0.69 to +0.39] and -0.10 [-0.56 to +0.36], respectively); however, 
these three meta-analyses contained only a single study. 
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The meta-analyses of relapse prevention 
Here there was a significant effect of individual CBT compared to TAU for the outcome ‘any 
relapse’  in a meta-analysis of 4 studies (risk ratio (RR) 0.67 [0.53 to 0.86]). However, this 
meta-analysis failed to include a large trial by Scott et al3, even though it was included in 
subsequent meta-analyses examining depressive and manic relapses separately. When this 
trial, which had negative findings, is added to the meta-analysis, the overall result becomes 
non-significant (RR 0.79 [0.59 to 1.06]) (see Figure 1). (NCCMH have not responded to a 
request to provide more information on the decision to exclude this trial.) 
 
Study name Statistics for each study Relapse / Total Risk ratio and 95% CI
Risk Lower Upper 
ratio limit limit Z-Value p-Value Therapy Control
Ball 2006 0.88 0.54 1.43 -0.52 0.60 13 / 25 16 / 27
Jones 2013 0.60 0.36 0.99 -2.01 0.04 12 / 29 20 / 29
Lam 2003 0.58 0.41 0.84 -2.93 0.00 21 / 48 36 / 48
Zaretsky 2008 1.15 0.38 3.55 0.25 0.80 6 / 26 4 / 20
Scott 2006* 1.04 0.82 1.32 0.31 0.75 67 / 127 64 / 126
0.79 0.59 1.07 -1.54 0.12
0.5 1 2
Favours CBT Favours control
 Figure 1. The NCCMH meta-analysis of CBT versus TAU for the outcome ‘any relapse’ 
modified to include the trial by Scott et al3. 
  
Two other meta-analyses (which both consisted of only one trial) found no benefit on relapse 
rates for either individual CBT versus active control (RR 1.13 [0.81 to 1.58]) or group CBT 
versus TAU (RR 1.17 [0.72 to 1.91]).  
 
Meta-analyses examining the effects of psychoeducation on relapse had inconsistent findings. 
One, that included three studies of individual psychoeducation versus TAU found no benefit 
(RR 0.81 [0.64 to 1.02]). On the other hand, a meta-analysis of two trials of carer-based 
psychoeducation versus TAU did find a significant effect (RR 0.61 [0.44 to 0.86]). There 
were also positive effects for psychoeducation in two out of three other meta-analyses, but 
each of these only contained a single trial. 
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The composite meta-analyses 
One might be forgiven for wondering where, in this maze of contradictory findings, the 
evidence supporting NICE’s1 recommendations comes from. The answer seems to lie in the 
fact that NCCMH also carried out a numberof further meta-analyses  (30+)  that pooled data 
from different types of psychological intervention. One of these combined online 
psychoeducation (2 studies) and individual CBT (4 studies) and found a small, but significant 
benefit on depressive symptoms compared to TAU at post-treatment (SMD -0.23 [-0.53 to -
0.08]). However, a combined meta-analysis of five group interventions (psychoeducation, 
mindfulness based CBT, CBT, social cognition and interaction training and dialectical 
behaviour therapy, 8 studies altogether) was negative at end of treatment (SMD -0.24 [-0.64 
to +0.16]). In the same way, the combined relapse-preventing effects of three individual 
psychological interventions (psychoeducation, therapy for medication adherence and CBT, 5 
studies altogether) compared to TAU was found to be significant (RR 0.74 [0.63 to 0.87]), 
but those for three group interventions (psychoeducation, CBT and mindfulness based 
cognitive therapy, 5 trials altogether) were not (RR 0.86 [0.61 to 1.20]).  
 
Combining psychological interventions does not, it seems, result in findings that are any less 
contradictory. Nor is the logic behind this strategy easy to understand, particularly when the 
interventions that were grouped together were quite different. 
 
Risk of bias 
Nowadays, it is considered essential to take study quality into account when interpreting 
results from meta-analysis4, 5. A clear consensus of opinion also suggests that the different 
sources of bias, including inadequate randomization, lack of blindness and failure to control 
for attrition among others, should be rated separately, not by means of a single quality scale. 
NCCMH rated multiple aspects of quality for all the studies that were included in their meta-
analyses, and NICE combined these ratings in a table that summarized the findings of some 
of the composite meta-analyses (Tables 34 and 35, p.257-8). At post-treatment, almost all the 
meta-analyses were based on studies that were rated as being of low or very low quality (the 
only exception was the outcome of hospitalization for collaborative care versus TAU, which 
received a ‘moderate’ rating). The same was true at follow-up, where only a meta-analysis of 
individual psychological interventions versus TAU for the outcome of relapse received a 
‘moderate’ rating. 
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This being the case, one might expect there to be caveats about the positive findings that 
emerged. Yet in the section of the NICE1 guideline ‘Linking evidence to recommendations’ 
(p262), cautionary notes are conspicuously absent: it is simply stated that there is evidence 
that psychological interventions may improve symptoms and reduce the risk of relapse and 
hospitalisation, ‘though the evidence for particular psychological interventions varies in 
quality’. Group interventions, integrated cognitive and interpersonal therapy and 
psychoeducation for families are described as showing promising results. 
 
Are NICE’s recommendations for psychological treatments evidence-based? 
NICE guidelines provide what is in effect a blueprint for good clinical practice. They are not 
statutary, although making them so has been suggested6. Via the NICE quality standards, they 
will almost certainly influence the decisions health commissioners make about what services 
they are going to fund. 
 
In the case of psychological treatment of bipolar disorder, the recommendations appear to go 
beyond the evidence. It seems likely that many clinicians and researchers would not come to 
the strong conclusions that NICE did based on what were more often than not negative meta-
analytic findings from mostly low-quality studies. There are also methodological concerns 
(failure to include the large well-conducted study by Scott et al3 in a key meta-analysis, not 
taking study quality into consideration), as well as statistical issues (carrying out a large 
number of meta-analyses but not correcting for multiple comparisons). Finally, something 
analogous to the increasingly recognized problem of selective reporting in clinical trials7 
seems to be operating: positive meta-analytic findings are cited approvingly while negative 
ones are played down or ignored.   
 
What can be done to remedy this situation? Firstly, carrying out vast numbers of meta-
analyses is not conducive to easy interpretation of their results. The blunderbuss approach 
taken by NCCMH needs to be replaced by something more targeted and, one is tempted to 
say, conventional. Secondly, study quality needs to be actively incorporated into the 
presentation of the conclusions – stating that an intervention is supported by meta-analysis 
but that all the included studies are low quality at best gives a mixed message and is at worst 
a contradiction in terms. Thirdly, and perhaps most importantly, the whole approach to the 
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interpretation of meta-analytic findings needs to be more tough-minded and critical; giving 
any appearance of setting the bar for this too low can only lead to doubts about rigour and 
impartiality.  
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